Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | TACR3 | P29371 | 4/20 | 0.61 |
| ▸ | TACR2 | P21452 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KCNK3 | O14649 | 8/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098915 | 1.00 | KDM4E (0.64) | KDM4EHIF1APKMTACR3TACR2 | |
| SCHEMBL6100469 | 0.91 | TACR3 (0.65) | KDM4EHIF1ATACR3TACR2ALDH1A1 | |
| SCHEMBL6100475 | 0.91 | TACR3 (0.65) | KDM4EHIF1ATACR3TACR2ALDH1A1 | |
| SCHEMBL6098802 | 0.90 | TACR3 (0.64) | KDM4EHIF1ATACR3TACR2ALDH1A1 | |
| SCHEMBL6098805 | 0.90 | TACR3 (0.64) | KDM4EHIF1ATACR3TACR2ALDH1A1 | |
| SCHEMBL6099742 | 0.89 | TACR3 (0.62) | KDM4EHIF1APKMTACR3TACR2 | |
| SCHEMBL6099750 | 0.89 | TACR3 (0.62) | KDM4EHIF1APKMTACR3TACR2 | |
| SCHEMBL6100583 | 0.88 | TACR3 (0.61) | HIF1ATACR3TACR2ALDH1A1KCNK3 | |
| SCHEMBL6100587 | 0.88 | TACR3 (0.61) | HIF1ATACR3TACR2ALDH1A1KCNK3 | |
| SCHEMBL6099810 | 0.87 | TACR3 (0.60) | KDM4EHIF1ATACR3TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041664-B2 | 2-aminoquinolinecarboxamides: neurokinin receptor ligands | NEUROGEN CORPORATION (US) | 2006-05-09 | — | — | US | claimed |
| US-20040229907-A1 | 2-Aminoquinolinecarboxamides: neurokinin receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2004-11-18 | — | — | US | claimed |
| US-6369053-B1 | CENTRAL NERVOUS SYSTEM AND PERIPHERAL DISEASES; ALSO USEFUL AS PROBES FOR THE LOCALIZATION OF CELL SURFACE RECEPTORS; NONPEPTIDE NK-3 RECEPTOR ANTAGONISTS | NEUROGEN CORPORATION | 2002-04-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229907-A1 | 2-Aminoquinolinecarboxamides: neurokinin receptor ligands | OPRL1, OPRK1, KCNQ3 | KDM4E 3541/4885HIF1A 3360/4885PKM 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.